3
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Lung Neoplasms
1
Liver Neoplasms
1
Head and Neck Neoplasms
1
Colonic Neoplasms
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
Fluorouracil
7
Oxaliplatin
6
Nivolumab
5
Leucovorin
5
fludarabine
4
Paclitaxel
4
Docetaxel
4
Cyclophosphamide
4
Capecitabine
4
zimberelimab
3
pembrolizumab
3
aldesleukin
3
Trastuzumab
3
Ramucirumab
3
ulixertinib
2
trastuzumab deruxtecan
2
fludarabine phosphate
2
Specimen Handling
2
Irinotecan
2
Cisplatin
2
zolbetuximab
1
zanidatamab
1
trifluridine tipiracil drug combination
1
trastuzumab biosimilar HLX02
1
trametinib
1
toripalimab
1
tislelizumab
1
sodium propionate
1
sapanisertib
1
relatlimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Stomach Neoplasms
×
Radionuclide Imaging
×
30 days
×
Clear all
NCT06904365
2026-05-18
OvAR-Y
Washington University School of Medicine
Active not recruiting
10 enrolled